SCHEMBL25323906

SCHEMBL25323906

Cn1cc(Br)c(-c2ccc(Cl)cn2)n1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.41
CASP3 P42574 1/20 0.37
NR1H4 Q96RI1 1/20 0.35
CSNK1D P48730 3/20 0.34
MAPK14 Q16539 2/20 0.34
HTR2A P28223 1/20 0.34
CNR2 P34972 1/20 0.34
MAPT P10636 3/20 0.34
ALDH1A1 P00352 1/20 0.34
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
MMP12 P39900 1/20 0.33
KMT2A Q03164 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ADCY10 Q96PN6 1/20 0.33
FGFR3 P22607 1/20 0.33
KDR P35968 1/20 0.33
GRM5 P41594 1/20 0.32
PDE2A O00408 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25324100 0.83 CCR1 (0.48) SMN1; SMN2CSNK1DMAPK14GRM5
SCHEMBL25323855 0.82 CSNK1D (0.50) CSNK1DMAPK14HTR2AADCY10KDR
SCHEMBL25323918 0.78 CSNK1D (0.34) SMN1; SMN2CSNK1DMAPK14HTR2APDE2A
SCHEMBL25324559 0.76 HTR2A (0.40) SMN1; SMN2CSNK1DMAPK14HTR2AALDH1A1
SCHEMBL9933095 0.75 SMN1; SMN2 (0.49) SMN1; SMN2CSNK1DMAPK14HTR2AMAPT
SCHEMBL25323581 0.75 CSNK1D (0.34) CSNK1DMAPK14NPC1RAB9A
SCHEMBL25320188 0.75 SMN1; SMN2 (0.32) SMN1; SMN2NPC1RAB9A
SCHEMBL30509509 0.75 SMN1; SMN2 (0.32) SMN1; SMN2NPC1RAB9A
SCHEMBL13874006 0.75 KDM4E (0.43) SMN1; SMN2MAPTALDH1A1NPC1RAB9A
SCHEMBL25324681 0.73 MAP4K4 (0.54) SMN1; SMN2CSNK1DMAPK14GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339900-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-26 US disclosed
US-20230339900-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-26 US disclosed
US-20230339900-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-26 US disclosed
EP-4214199-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN Pharmaceutica NV (BE) 2023-07-26 EP disclosed
CN-116490503-A Casein kinase 1 delta modulators 詹森药业有限公司 2023-07-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339900-A1 CASEIN KINASE 1 DELTA MODULATORS CSNK1D, CSNK1A1, CSNK2A1 SMN1; SMN2 1386/4885CASP3 4236/4885NR1H4 1130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.